The mission of the Arizona Cancer Center (AZCC) is to prevent and cure cancer. To continue that mission, this application requests a 5-year renewal of the Cancer Center Support Grant (CCSG). The AZCC was founded originally as a Division of the College of Medicine (COM), University of Arizona (UA) in 1976. It obtained a CCSG in 1978 and was designated a Comprehensive Cancer Center by the NCI in 1990. In 2008, the Cancer Center became a part of the Arizona Health Sciences Center campus directly reporting to the Vice Provost for Health Affairs. To accomplish our mission, the basic and translational/clinical and cancer prevention and control research is carried out in five programs, including cancer biology and genetics, cancer imaging, gastrointestinal cancer, therapeutic development and cancer prevention and control. These programs are supported by 12 shared services, which help the AZCC (the whole) be greater than the sum of the parts. Since the last renewal, the AZCC team has still been able to increase our research efforts based on increased donor and institutional support. Our peer reviewed funding has remained stable despite decreased funding available at the national level and we have garnered additional program projects and a Lymphoma SPORE and successfully renewed our Gl cancer SPORE. Those accomplishments demonstrate the interdisciplinary activities of the Cancer Center. As we hope the reviewers will see, the team has made considerable progress in their basic and clinical science. The renewal outlined in this application is critical to keep us working to accomplish our mission.
This Cancer Center Support Grant is requested to provide support for the critical infrastructure and shared resources needed by our scientific program investigators to seek new treatment methods to both prevent and cure cancer.
|Dickinson, Sally E; Janda, Jaroslav; Criswell, Jane et al. (2016) Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Cancer Prev Res (Phila) 9:215-24|
|Schissler, A Grant; Li, Qike; Chen, James L et al. (2016) Analysis of aggregated cell-cell statistical distances within pathways unveils therapeutic-resistance mechanisms in circulating tumor cells. Bioinformatics 32:i80-i89|
|Banerjee, Bhaskar; Shaheen, Nicholas J; Martinez, Jessica A et al. (2016) Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients. Cancer Prev Res (Phila) 9:528-33|
|Pulko, Vesna; Davies, John S; Martinez, Carmine et al. (2016) Human memory T cells with a naive phenotype accumulate with aging and respond to persistent viruses. Nat Immunol 17:966-75|
|Warfel, Noel A; Sainz, Alva G; Song, Jin H et al. (2016) PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther 15:1637-47|
|Thomson, Cynthia A; Ho, Emily; Strom, Meghan B (2016) Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutr Rev 74:432-43|
|Tsikitis, Vassiliki L; Potter, Amiee; Mori, Motomi et al. (2016) MicroRNA Signatures of Colonic Polyps on Screening and Histology. Cancer Prev Res (Phila) 9:942-949|
|Hanke, Neale T; Garland, Linda L; Baker, Amanda F (2016) Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol 142:549-60|
|Kohler, Lindsay N; Garcia, David O; Harris, Robin B et al. (2016) Adherence to Diet and Physical Activity Cancer Prevention Guidelines and Cancer Outcomes: A Systematic Review. Cancer Epidemiol Biomarkers Prev 25:1018-28|
|Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35|
Showing the most recent 10 out of 1161 publications